Drugs for Gastrointestinal Diseases Practice Questions

Q: Which of the following is NOT a side effect of cimetidine?

Atrophic gastritis. **Explanation:** Cimetidine is a first-generation **H2-receptor antagonist** used to reduce gastric acid secretion. While effective, it is notorious for its significant side-effect profile compared to newer agents like Ranitidine or Famotidine. **Why Atrophic Gastritis is the correct answer:** Atrophic gastritis is characterized by chronic inflammation and thinning of the gastric mucosa, often leading to a loss of parietal cells. It is typically caused by *H. pylori* infection or autoimmune processes. Cimetidine **does not cause** atrophic gastritis; rather, it is used to treat conditions like peptic ulcers and GERD. Long-term use of Proton Pump Inhibitors (PPIs), not H2 blockers, is more commonly associated with concerns regarding gastric atrophy and hypergastrinemia. **Analysis of Incorrect Options:** Cimetidine possesses unique anti-androgenic properties that are not shared by other H2 blockers: * **Impotence & Gynaecomastia (Options A & B):** Cimetidine binds to androgen receptors and inhibits the binding of dihydrotestosterone (DHT). It also inhibits the metabolism of estradiol, leading to increased estrogen levels. This hormonal imbalance results in erectile dysfunction and breast tissue enlargement in men. * **Galactorrhea (Option D):** Cimetidine can increase serum prolactin levels, which may lead to inappropriate milk secretion (galactorrhea) in both men and women. **High-Yield NEET-PG Pearls:** * **Enzyme Inhibition:** Cimetidine is a potent **P450 enzyme inhibitor**. It increases the toxicity of drugs like Warfarin, Phenytoin, and Theophylline. * **BBB Crossing:** Unlike newer H2 blockers, Cimetidine crosses the blood-brain barrier and can cause **mental confusion**, especially in elderly patients with renal impairment. * **Mnemonic:** Remember the "4 Gs" of Cimetidine side effects: **G**ynaecomastia, **G**alactorrhea, **G**uts (CYP inhibition), and **G**uide (Mental confusion).

Q: All of the following are true about prostaglandin E2 except?

It stimulates gastric acid secretion. **Explanation:** Prostaglandins (PGs), specifically **PGE2 and PGI2**, play a vital role in maintaining the integrity of the gastric mucosa. This question tests the understanding of their physiological actions on the stomach. **Why Option C is correct:** PGE2 is a potent **inhibitor** of gastric acid secretion, not a stimulator. It binds to **EP3 receptors** on parietal cells, which are coupled to Gi proteins. This leads to the inhibition of adenylyl cyclase, decreased intracellular cAMP levels, and a subsequent reduction in the activity of the H+/K+ ATPase pump (proton pump). **Analysis of incorrect options:** * **Option A:** PGE2 and PGI2 are indeed the primary prostaglandins synthesized by the gastric mucosa. They are produced via the COX-1 pathway under physiological conditions. * **Option B:** Aspirin and other NSAIDs are non-selective inhibitors of the Cyclooxygenase (COX) enzymes. By inhibiting COX-1, they block the biosynthesis of PGE2, which is the primary mechanism behind NSAID-induced peptic ulcers. * **Option C:** PGE2 promotes mucosal blood flow by causing **vasodilation** of the submucosal microvasculature. This ensures adequate nutrient delivery and removal of back-diffused acid. **NEET-PG High-Yield Pearls:** 1. **Cytoprotective Triad:** PGE2 protects the stomach by: (1) Decreasing acid secretion, (2) Increasing mucus and bicarbonate secretion, and (3) Increasing mucosal blood flow. 2. **Misoprostol:** A synthetic PGE1 analog used clinically to prevent NSAID-induced gastric ulcers. 3. **Side Effects of Misoprostol:** Diarrhea (most common) and uterine contractions (contraindicated in pregnancy as it can cause abortion).

Q: Which of the following does not change the pH of the stomach?

Sucralfate. ### Explanation The correct answer is **A. Sucralfate**. **1. Why Sucralfate is correct:** Sucralfate is a **cytoprotective agent**, not an antacid or an antisecretory drug. It is a complex of aluminum hydroxide and sulfated sucrose. In an **acidic environment (pH < 4)**, it polymerizes into a sticky, viscous paste that binds selectively to the exposed proteins (albumin, fibrinogen) in the ulcer base. This creates a physical barrier against acid, pepsin, and bile. Crucially, sucralfate **does not neutralize gastric acid** nor does it inhibit its secretion; therefore, it does not change the pH of the stomach. **2. Why the other options are incorrect:** * **B & D (H2 Blockers / Ranitidine):** Ranitidine is a competitive antagonist of H2 receptors on parietal cells. By blocking histamine-induced acid secretion, these drugs significantly **increase gastric pH** (make it less acidic) [1]. * **C (Omeprazole):** This is a Proton Pump Inhibitor (PPI) that irreversibly inhibits the $H^+/K^+$-ATPase pump. It is the most potent class of drugs for **increasing gastric pH** [1]. **3. Clinical Pearls for NEET-PG:** * **Activation Requirement:** Sucralfate requires an acidic medium to polymerize. Therefore, it should **not** be given simultaneously with antacids, H2 blockers, or PPIs, as they raise the pH and prevent its activation. * **Side Effects:** The most common side effect of Sucralfate is **constipation** (due to the aluminum content) [1]. * **Drug Interactions:** It can adsorb other drugs (e.g., Tetracycline, Digoxin, Phenytoin); hence, a 2-hour gap is recommended between doses [1]. * **Misoprostol:** Another drug that protects the mucosa but *does* slightly decrease acid secretion (unlike Sucralfate).

Q: Erythromycin is given in intestinal hypomotility because?

It binds to motilin receptors. **Explanation:** **Mechanism of Action (Why D is correct):** Erythromycin, a macrolide antibiotic, acts as a **prokinetic agent** by mimicking the action of the endogenous peptide hormone **motilin**. It acts as a non-peptide motilin receptor agonist. These receptors are primarily located on the smooth muscles of the gastrointestinal tract (stomach and duodenum). Binding to these receptors triggers Phase III of the **Migrating Motor Complex (MMC)**, leading to powerful antral contractions that accelerate gastric emptying and intestinal transit. **Analysis of Incorrect Options:** * **A & B:** While Erythromycin is an antibiotic that affects bacterial counts, its prokinetic effect is independent of its antimicrobial properties. In the context of hypomotility, the drug is used for its pharmacological action on smooth muscle receptors, not for its effect on gut flora. * **C:** Erythromycin does not exert its primary GI effect through adenylyl cyclase. Prokinetic agents like 5-HT4 agonists (e.g., Prucalopride) increase cAMP via adenylyl cyclase, but Erythromycin specifically targets motilin receptors. **High-Yield Clinical Pearls for NEET-PG:** * **Clinical Use:** It is the drug of choice for **Diabetic Gastroparesis** and is also used in post-operative ileus and to clear the stomach of blood before endoscopy in upper GI bleeds. * **Tachyphylaxis:** A major limitation of Erythromycin as a prokinetic is the rapid development of tolerance (tachyphylaxis) due to down-regulation of motilin receptors. * **Side Effects:** Common GI side effects include abdominal cramps and nausea. It is also a known inhibitor of the **CYP3A4 enzyme**, leading to significant drug interactions.

Q: Ursodeoxycholic acid is a:

Gallstone dissolving drug. **Explanation:** **Ursodeoxycholic acid (UDCA)** is a naturally occurring hydrophilic bile acid that makes up a small fraction of the human bile acid pool. It is primarily used as a **gallstone dissolving drug** (Option C). **Mechanism of Action:** UDCA works by suppressing the synthesis and secretion of cholesterol from the liver and inhibiting its intestinal absorption. This leads to the desaturation of bile with cholesterol, allowing for the gradual dissolution of radiolucent (cholesterol) gallstones. It also has cytoprotective effects in the liver by replacing toxic hydrophobic bile acids. **Analysis of Incorrect Options:** * **Option A (Urinary stone dissolving drug):** These include agents like potassium citrate (for uric acid/cystine stones) or acetazolamide. UDCA has no effect on renal calculi. * **Option B (Thrombolytic drug):** These are "clot busters" like Streptokinase or Alteplase used in MI or stroke. * **Option D (Antifibrinolytic):** These drugs, such as Tranexamic acid, prevent the breakdown of fibrin to control bleeding. **NEET-PG High-Yield Pearls:** 1. **Indications:** UDCA is the drug of choice for **Primary Biliary Cholangitis (PBC)**. It is also used for dissolving small, non-calcified cholesterol gallstones in patients who are unfit for surgery. 2. **Prerequisite for Gallstones:** For UDCA to work, the gallbladder must be **functional** (patent cystic duct) and stones must be **radiolucent** (cholesterol-rich). 3. **Obstetric Use:** It is the preferred treatment for **Intrahepatic Cholestasis of Pregnancy (ICP)** to reduce pruritus and improve liver enzymes.

Q: Which of the following selectively acts on 5HT3 receptors?

Ondansetron. **Explanation:** **Ondansetron** is the correct answer because it is a prototype **selective 5-HT3 receptor antagonist** [1], [3]. These receptors are ligand-gated ion channels located peripherally on vagal nerve terminals and centrally in the Chemoreceptor Trigger Zone (CTZ) [1]. By blocking these receptors, Ondansetron effectively inhibits the emetic reflex, making it the drug of choice for **Chemotherapy-Induced Nausea and Vomiting (CINV)** and post-operative vomiting [1], [3]. **Analysis of Incorrect Options:** * **Bupropion:** An atypical antidepressant that acts as a Norepinephrine-Dopamine Reuptake Inhibitor (NDRI). It is also used for smoking cessation but has no significant activity at 5-HT3 receptors. * **Sumatriptan:** A selective **5-HT1B/1D receptor agonist** used in the acute treatment of migraine to cause intracranial vasoconstriction. * **Renzapride:** A substituted benzamide that acts as a **5-HT4 receptor agonist** and a 5-HT3 antagonist. Unlike Ondansetron, it is not *selective* for 5-HT3 and is primarily studied for its prokinetic effects in IBS. **High-Yield Clinical Pearls for NEET-PG:** * **Side Effects:** The most common side effect of Ondansetron is **headache** and constipation. A critical ECG finding to remember is **QT interval prolongation**. * **Drug of Choice:** Ondansetron is the preferred agent for vomiting caused by radiotherapy and cytotoxic drugs (cisplatin), but it is **ineffective** in motion sickness (where H1 and M1 blockers are used) [1], [2]. * **Other 5-HT3 Antagonists:** Palonosetron (longest half-life) and Granisetron [1], [3].

Q: Fosaprepitant is used as:

Antiemetic. **Explanation:** **Fosaprepitant** is a water-soluble prodrug of **Aprepitant**. It belongs to the class of **Neurokinin-1 (NK1) receptor antagonists**. 1. **Why it is an Antiemetic:** The mechanism involves blocking the binding of **Substance P** to NK1 receptors located in the *area postrema* (Chemoreceptor Trigger Zone) and the nucleus tractus solitarius. It is specifically indicated for the prevention of both acute and delayed phases of **Chemotherapy-Induced Nausea and Vomiting (CINV)**, particularly with highly emetogenic drugs like Cisplatin. It is usually used in a "triple regimen" along with a 5-HT3 antagonist (e.g., Ondansetron) and a corticosteroid (e.g., Dexamethasone). 2. **Why other options are incorrect:** * **Antidepressant:** While Substance P was once researched for mood disorders, NK1 antagonists have not shown clinical efficacy as antidepressants. Common antidepressants include SSRIs or TCAs. * **Antihypertensive:** Fosaprepitant has no effect on peripheral vascular resistance or cardiac output. * **Diuretic:** It does not act on the nephrons to promote diuresis. **High-Yield Clinical Pearls for NEET-PG:** * **Route:** Fosaprepitant is administered **intravenously**, whereas Aprepitant is given orally. * **Metabolism:** It is a substrate, inducer, and inhibitor of **CYP3A4**. It can decrease the concentration of Warfarin (monitor INR) and increase the concentration of Dexamethasone (dose reduction of steroid is required). * **Other NK1 Antagonists:** Rolapitant and Netupitant (often combined with Palonosetron).

Q: Octreotide is useful in esophageal varices. It is a synthetic analogue of somatostatin. Which statement regarding this drug is true?

It is longer acting than somatostatin. **Explanation:** **1. Why Option B is Correct:** Somatostatin is a natural hormone with an extremely short half-life (approximately 1–3 minutes), making it clinically impractical for continuous use without constant infusion. **Octreotide** is a synthetic octapeptide analogue designed to be more potent and significantly **longer-acting** (half-life of ~1.5 to 2 hours). This extended duration of action allows for subcutaneous or intravenous bolus administration. In esophageal varices, it works by causing selective splanchnic vasoconstriction, thereby reducing portal venous pressure and controlling bleeding. **2. Why Other Options are Incorrect:** * **Option A:** Octreotide is a peptide. Like insulin, it is degraded by gastric enzymes if taken orally. It must be administered parenterally (SC or IV). * **Option C:** Octreotide actually **inhibits** intestinal secretion and motility. Therefore, it is used to *treat* secretory diarrhea (e.g., in Carcinoid syndrome or VIPoma). Its major gastrointestinal side effects are actually **steatorrhea** (due to inhibition of pancreatic enzymes) and **gallstones/biliary sludge** (due to inhibition of gallbladder contraction). **3. NEET-PG High-Yield Pearls:** * **Mechanism in Varices:** It inhibits the release of glucagon and other vasodilator peptides, leading to indirect splanchnic vasoconstriction. * **Clinical Uses:** Acromegaly (inhibits GH), Secretory diarrheas (VIPoma, Carcinoid), and Acute variceal bleeding. * **Drug of Choice:** While Octreotide is commonly used, **Terlipressin** (a vasopressin analogue) is often considered the drug of choice for esophageal varices as it has been shown to improve survival rates. * **Side Effect Profile:** Long-term use carries a high risk of **cholelithiasis** (gallstones) in up to 25% of patients.

Q: A patient on cisplatin therapy develops intractable vomiting on the third day of treatment. What is the agent of choice for controlling this vomiting?

Aprepitant. ### Explanation The key to answering this question lies in distinguishing between **acute** and **delayed** chemotherapy-induced nausea and vomiting (CINV). **1. Why Aprepitant is Correct:** Cisplatin is a highly emetogenic drug. It causes vomiting in two phases: * **Acute phase (<24 hours):** Primarily mediated by **Serotonin (5-HT3)** release. * **Delayed phase (2–5 days):** Primarily mediated by **Substance P** acting on **Neurokinin-1 (NK1) receptors** in the area postrema. Since the patient is experiencing vomiting on the **third day**, it is classified as delayed emesis. **Aprepitant**, an NK1 receptor antagonist, is the drug of choice for the prevention and treatment of delayed CINV. **2. Why Other Options are Incorrect:** * **Ondansetron (5-HT3 antagonist):** While it is the gold standard for *acute* emesis, it has limited efficacy in the *delayed* phase (after 24 hours). * **Metoclopramide (D2 antagonist):** It was historically used in high doses for cisplatin, but it is less effective than 5-HT3 or NK1 antagonists and carries a risk of extrapyramidal side effects. * **Prochlorperazine (D2 antagonist):** This is a low-potency antipsychotic used for mild-to-moderate nausea (e.g., motion sickness or post-operative), but it is insufficient for highly emetogenic cisplatin-induced delayed emesis. ### High-Yield NEET-PG Pearls: * **Triple Therapy for Cisplatin:** The current recommendation for highly emetogenic chemotherapy is a combination of **NK1 antagonist (Aprepitant) + 5-HT3 antagonist (Ondansetron) + Dexamethasone.** * **Aprepitant Metabolism:** It is a substrate, inhibitor, and inducer of **CYP3A4**. * **Palonosetron:** A second-generation 5-HT3 antagonist with a longer half-life that has some efficacy in delayed emesis, but NK1 antagonists remain the primary choice.

Question 1

Which of the following is NOT a side effect of cimetidine?

Accepted Answer

Atrophic gastritis

Answer

Impotence

Answer

Gynaecomastia

Answer

Galactorrhea

Question 2

All of the following are true about prostaglandin E2 except?

Accepted Answer

It stimulates gastric acid secretion

Answer

It is the principal prostaglandin synthesized in the stomach

Answer

Its biosynthesis is inhibited by aspirin

Answer

It causes dilatation of submucosa blood vessels

Question 3

Which of the following does not change the pH of the stomach?

Accepted Answer

Sucralfate

Answer

H2 blocker

Answer

Omeprazole

Answer

Ranitidine

Question 4

Erythromycin is given in intestinal hypomotility because?

Accepted Answer

It binds to motilin receptors

Answer

It increases bacterial count

Answer

It decreases bacterial count

Answer

It binds to adenylyl cyclase

Question 5

Ursodeoxycholic acid is a:

Accepted Answer

Gallstone dissolving drug

Answer

Urinary stone dissolving drug

Answer

Thrombolytic drug

Answer

Antifibrinolytic

Question 6

Which of the following selectively acts on 5HT3 receptors?

Accepted Answer

Ondansetron

Answer

Bupropion

Answer

Sumatriptan

Answer

Renzapride

Question 7

Fosaprepitant is used as:

Accepted Answer

Antiemetic

Answer

Antidepressant

Answer

Antihypertensive

Answer

Diuretic

Question 8

Octreotide is useful in esophageal varices. It is a synthetic analogue of somatostatin. Which statement regarding this drug is true?

Accepted Answer

It is longer acting than somatostatin

Answer

It can be given orally

Answer

Its major adverse effect is secretory diarrhea

Answer

All of the above

Question 9

What is the drug of choice for ulcerative colitis?

Accepted Answer

5-aminosalicylic acid

Answer

Salazopyrine

Answer

Prednisolone

Answer

Mercaptopurine

Question 10

A patient on cisplatin therapy develops intractable vomiting on the third day of treatment. What is the agent of choice for controlling this vomiting?

Accepted Answer

Aprepitant

Answer

Ondansetron

Answer

Metoclopramide

Answer

Prochlorperazine

Drugs for Gastrointestinal Diseases — MCQs

Drugs for Gastrointestinal Diseases — MCQs

On this page

Practice by Chapter

Want unlimited practice?